Protein Kinase Inhibitors: all 15,278 studies that test it

Page 87 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Safety and Effectivness of Quercetin & Dasatinib on Epigenetic AgingStatus unknownNCT04946383Phase 2
• Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy ParticipantsCompletedNCT04944771Phase 1
• Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPAStatus unknownNCT04944524Phase 4
• Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisStatus unknownNCT04944069Not applicable
• A Study of TQ05105 in Patients With Chronic Graft Versus Host DiseaseActive, not recruitingNCT04944043Phase 1/2
• Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile PatientsActive, not recruitingNCT04943224Phase 2
• Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisActive, not recruitingNCT04943198Phase 2
• A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)TerminatedNCT04941404Phase 1/2
• Dedicated Drug-Drug Interaction (DDI) Study in Healthy VolunteersCompletedNCT04939467Phase 1
• A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;CompletedNCT04939363Phase 2
• Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04939272Phase 1/2
• Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingNCT04938817Phase 1/2
• Ursodeoxycholic Acid (Udca) as a Local Drug Delivery Agent in the Treatment of Intra-bony DefectsStatus unknownNCT04937023Not applicable
• A Study of NB003 in Patients With Advanced MalignanciesCompletedNCT04936178Phase 1
• A Study to Explore the Effect of Acid-reducing AgentsCompletedNCT04935112Phase 1
• First in Human Study of ORG-129 in Healthy VolunteersCompletedNCT04933565Phase 1
• The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP PatientsStatus unknownNCT04933526Phase 4
• Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung CancerStatus unknownNCT04933175Phase 2
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular CarcinomaCompletedNCT04930315Phase 2
• Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal CancerStatus unknownNCT04929652Phase 1/2
• The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid ArthritisStatus unknownNCT04927000Phase 4
• Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04926532Phase 1/2
• Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis ManagementActive, not recruitingNCT04925973Phase 2
• A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)CompletedNCT04925141Phase 4
• A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung CancerTerminatedNCT04924192Phase 2
• Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT04923945Phase 3
• Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedNCT04923932Phase 2
• Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsActive, not recruitingNCT04923906Phase 3
• Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung CancerActive, not recruitingNCT04922658Phase 2
• Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingNCT04920708Phase 2
• Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCActive, not recruitingNCT04919811Phase 2
• Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaCompletedNCT04919642Phase 2
• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingNCT04917809Phase 2
• A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome PatientsCompletedNCT04916756Phase 1/2
• Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersTerminatedNCT04916236Phase 1
• A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196CompletedNCT04914936Phase 1
• A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04914286Phase 1/2
• Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCCStatus unknownNCT04911959Phase 1/2
• Surufatinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT04910854Phase 2
• Follow-up of NAFLD Patients With MRI-PDFFCompletedNCT04910178Phase 4
• Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult ParticipantsCompletedNCT04909242Phase 1
• Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)TerminatedNCT04908956Phase 2
• Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantTerminatedNCT04908735Phase 2
• A Drug-drug Interaction Study of Avapritinib and MidazolamCompletedNCT04908176Phase 1
• Acalabrutinib in CNSLActive, not recruitingNCT04906902Phase 1/2
• A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced SarcomasWithdrawnNCT04906876Phase 2
• Study Of ATRN-119 In Patients With Advanced Solid TumorsCompletedNCT04905914Phase 1/2
• Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLCStatus unknownNCT04905550Phase 2
• A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedNCT04905043Phase 1
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
• Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerCompletedNCT04903652Phase 2
• A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy ParticipantsCompletedNCT04901923Phase 1
• Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid TumorsTerminatedNCT04901806Phase 1
• Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerStatus unknownNCT04901754Phase 2
• Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 2
• Fulvestrant + Neratinib In Breast CancerWithdrawnNCT04901299Phase 2
• Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell LymphomaStatus unknownNCT04899570Phase 2
• Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
• Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04899427Phase 2
• Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.WithdrawnNCT04896320Phase 1/2
• Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCStatus unknownNCT04895930Phase 2
• Lung Cancer With Copanlisib and DurvalumabCompletedNCT04895579Phase 1
• Vactosertib and Durvalumab in Gastric CancerStatus unknownNCT04893252Phase 2
• Sirolimus in Treatment of Proteinuric Flares of Lupus NephritisStatus unknownNCT04892212Phase 2/3
• TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT04891900Not applicable
• EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform TrialTerminatedNCT04891133Phase 2/3
• A Phase Ib / IIA Study of AL8326 in Small Cell Lung CancerStatus unknownNCT04890795Phase 1/2
• A Phase I Study of AL8326 in Advanced Solid TumorStatus unknownNCT04890587Phase 1
• Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedNCT04890236Early Phase 1
• To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT04888715Phase 1
• Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaCompletedNCT04888429Phase 2
• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1
• Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)Active, not recruitingNCT04886804Phase 1
• Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
• Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib TreatmentStatus unknownNCT04882345Phase 2
• Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Phase 2
• SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyStatus unknownNCT04878107Phase 2
• The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
• A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With OmeprazoleCompletedNCT04876807Phase 1
• A Phase II Trial of Cabozantinib With Patients With Refractory GCTsCompletedNCT04876456Phase 2
• Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenibCompletedNCT04874207Phase 4
• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)TerminatedNCT04873895Phase 1
• Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerActive, not recruitingNCT04872985Phase 2
• Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
• A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerWithdrawnNCT04872608Phase 1
• Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownNCT04870190Phase 3
• Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1
• A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult ParticipantsCompletedNCT04867980Phase 1
• A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196CompletedNCT04867941Phase 1
• Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant RecipientsStatus unknownNCT04867720Phase 4
• An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
• A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT04866134Phase 1/2
• A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous ChemotherapyStatus unknownNCT04866108Phase 2
• Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the StomachWithdrawnNCT04863430Phase 2
• A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionStatus unknownNCT04863365Phase 3
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
• The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or ParagangliomaCompletedNCT04860700Phase 2

← Protein Kinase Inhibitors overview